IM
MRNS

Islet Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Islet Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-540,000
Closed -$3.73M – 39
2023
Q1 		$3.73M Buy
540,000
+140,000
+35% +$878K 1.81% 13
2022
Q4 		$1.59M Buy
+400,000
New +$1.97M 1.07% 29

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Islet Management's MRNS Position: Q2 2023 in Review

Islet Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2023, closing a stake of 30,000 shares — an estimated $207K sold.

Islet Management first reported a position in MRNS in Q4 2019 and held it in 6 quarters. The position peaked at $8.35M in Q3 2020. 106 funds tracked by Wall St. Rank hold MRNS as of Q2 2023.

  • Islet Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2023 after selling out during the quarter.
  • Islet Management sold 30,000 Marinus Pharmaceuticals, Inc shares in Q2 2023, an estimated $207K.
  • Islet Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2019 and held it in 6 quarters.
  • Islet Management's Marinus Pharmaceuticals, Inc position peaked at $8.35M in Q3 2020.
  • 106 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2023.

Based on Islet Management's 13F filing for Q2 2023, filed 14 Aug 2023.